Ultrapure sodium alginate produced by the company meets the requirements of in vivo implantation standards, and can be prepared into solutions, gel, microspheres, cell loaded microcapsules and other implant and interventional medical devices, providing new solutions for cell loading, embolization, filling and slow release for preclinical research of acute liver failure, tumor, diabetes, Parkinson's disease, heart failure, intractable pain, urinary incontinence and other diseases.